Bougienage followed by balloon dilation was done over several sessions. However bougienage proved to be ineffective as the bougie bent due to the high resistance within the stenosis (l " Fig. 3 ). Despite these therapeutic approaches no positive clinical results could be achieved. After neoplasia had been ruled out, argon plasma coagulation (APC) was done in re− peated sessions to ablate the circular hy− perkeratoses (l " Fig. 4 ), using a high fre− quency device (40 ± 60 W, 0.5 ± 0.6 l / min; BOWA, Gomaringen, Germany).
At the end of this treatment (l " Fig. 5 ), passage of the GIF−Q160 endoscope (9.8 mm) presented no problems. Initially an esophageal carcinoma had been suspected, but in multiple tissue biopsies the histopathological examina− tion revealed parts of a distinctively hy− perkeratotic squamous epithelium with basal cell proliferation without evidence of malignancy (l " Fig. 6 ). Using APC, successful desquamation of the hyperkeratotic areas, with re−epithe− lialization after thermal destruction of the tissue, was achieved. After comple− Severe high grade stenosing hyperkeratosis of the esophagus after ingestion of alkali: successful treatment by argon plasma coagulation Fig. 1 Esophagography with water−soluble iodine contrast agent, in left anterior oblique position, showed irregular mucosa of length approximately 9 cm (white arrowheads) in the mid esophagus, and high grade stenosis. tion of the treatment in October 2006, in− gestion of liquid and solid food was again possible and the patient had a notewor− thy increase in weight. In our patient, APC proved to be an effec− tive and safe procedure for treating an esophageal stenosis with distinctive hy− perkeratotic changes. Using this thera− peutic approach, stent implantation or a surgical procedure was avoided.
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Fig. 6 Representative microscopic findings: parts of a distinctively hyperkeratotic squa− mous epithelium with basal cell proliferation, without evidence of malignancy (hematoxy− lin±eosin [H&E], 4).
